Topical Latanoprost Acid for Female Androgenetic Alopecia: A Pilot Proof-Of-Concept Trial With Mechanistic Evidence of FP-Receptor Activation

    March 2026
    Adriana Rakowska, Małgorzata Dutkiewicz, Oliwia Zegrocka-Stendel, Dorota Dymkowska, Grzegorz Huszcza, Maciej Wierzbicki, Jarosław Walczak, Lidia Rudnicka, Katarzyna Koziak
    Image of study
    TLDR Topical latanoprost acid at 0.05% concentration improved hair growth in women with androgenetic alopecia.
    This pilot proof-of-concept trial investigated the effects of topical latanoprost acid on female androgenetic alopecia. Conducted with adult women, the study tested three concentrations (0.01%, 0.05%, and 0.1%) over 6 months. The 0.05% concentration showed the most consistent improvement in target-area hair count, with an average increase of 23.5 hairs/cm², along with reduced yellow dots and a shift to multi-hair follicular units. Safety was favorable, with no serious adverse events. Mechanistic assays indicated that latanoprost acid triggered rapid, concentration-dependent Ca²⁺ flux in human hair dermal papilla cells. These findings support further trials focusing on the 0.05% concentration.
    Discuss this study in the Community →

    Research cited in this study

    11 / 11 results